The Fund's resources are expected to be mobilized from various sources, including State budget allocations, voluntary contributions from domestic and foreign investors.
Imexpharm kicked off Q1 2025 with impressive results, reporting net revenue of VND594 billion and profit before tax of VND95 billion in Q1 2025, up 21 per cent and 23 per cent year-on-year (YoY), respectively.